Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

Pfizer acquires rights to 55 generic pills, 20 injectibles through new deals with Claris Lifesciences and Aurobindo (GenericsWeb)

Sytrinol (Polymethoxylated flavones, tocotrienols) – US: District Court N D Illinois rules patent co-owned by US not immunised from infringement or validity determinations (Patent Docs)

Thinking globally and strategically about intellectual property in the pharmaceutical space IP Think Tank podcast 19 May 2009 (IP Think Tank) (IP Think Tank)

Public health and the preservation of competitiveness: the role of the SPC (The SPC Blog)

WHO members near deal on IP, innovation and public health, with key question (Intellectual Property Watch)

Pfizer acquires rights to 55 generic pills, 20 injectibles through new deals with Claris Lifesciences and Aurobindo (GenericsWeb)

Africa: John Kilama, President of Global Bioscience Development Institute discusses need for formal IP system to foster growth in Africa (Afro-IP)

India: Novartis feels the heat of the Indian Summer. What is the fate of similar applications filed by Indian manufacturers? (Patent Office’s rejection of Glivec’s second variant) (Spicy IP) (Spicy IP)

Sweden: Anti-counterfeit barcode technology trialled in Sweden (Managing Intellectual Property)

US: ACLU, PUBPAT and others file lawsuit challenging constitutionality of patents on human genes associated with breast and ovarian cancer: Association for Molecular Pathology et al v USPTO et al (Inventive Step) (Holman’s Biotech IP Blog)

US: Biotech sector highly critical of Commission’s patent stand, new Marks & Clerk survey reports (IAM)

US: California Court of Appeal: assignment of contract, not patent in case concerning patent licence for PCR process for amplification of DNA: Applera Corp v MP Biomedicals (Property, intangible)

US: GSK’s Sherry Knowles responds to post on BIO session (Patent Docs)

US: For US healthcare reform and global health crises, both public and private efforts needed (PatentBIOtech)

Antara (Fenofibrate) – US: Paddock files ANDA to make generic version of Oscient’s Antara (GenericsWeb)

Cinacalcet (Sensipar) – US: Teva sues Amgen for process patent infringement (GenericsWeb)

Coreg (Carvedilol) – US: Teva, Zydux, Cadila settle Coreg patent suit (Patent Docs) (GenericsWeb)

Creatine ethyl ester – US: UneMed files complaint requesting ITC investigate unlawful import and sale of products falsely advertised as containing creatine ethyl ester by Bodyonics, Engineered Sports Technology, Proviant Technologies, Controlled Labs of New Rochelle, NRG-X Labs and San Corporation (ITC 337 Law Blog)

Protonix (Pantoprazole) – US: CAFC finds generic entry does not cause irreparable harm, affirms denial of preliminary injunction: Altana Pharma & Wyeth v Teva (The IP Factor)

Pulmicort (Budesonide) – US: Apotex barred from selling generic version of AstraZeneca’s Pulmicort prior to patent infringement trial (GenericsWeb)

Sytrinol (Polymethoxylated flavones, tocotrienols) – US: District Court N D Illinois rules patent co-owned by US not immunised from infringement or validity determinations (Patent Docs)

TroVax (5T4, pox virus vector) – US: Bavarian Nordic suit over TroVax survives motion to dismiss: Bavarian Nordic A/S v Oxford Biomedica Plc et al (Patent Docs)

Xyzal (Levocetirizine) – US: Synthon first generic ANDA filer for Xyzal oral solution (GenericsWeb)